

Review Article

Parkinson's Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson's Disease, If Anything?

J. Drouin-Ouellet¹ and R. A. Barker²

¹Neuroscience Axis, CHUL Research Center (CHUQ), T2-50, 2705 Boul. Laurier, Quebec City, QC, Canada G1V 4G2

²Department of Clinical Neurosciences, Cambridge Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, UK

Correspondence should be addressed to R. A. Barker, rab46@cam.ac.uk

Received 7 July 2012; Accepted 3 December 2012

Academic Editor: Pavla Jendelova

Copyright © 2012 J. Drouin-Ouellet and R. A. Barker. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Technologies allowing for the derivation of patient-specific neurons from somatic cells are emerging as powerful *in vitro* tools to investigate the intrinsic cellular pathological behaviours of the diseases that affect these patients. While the use of patient-derived neurons to model Parkinson's disease (PD) has only just begun, these approaches have allowed us to begin investigating disease pathogenesis in a unique way. In this paper, we discuss the advances made in the field of cellular reprogramming to model PD and discuss the pros and cons associated with the use of such cells.

1. Introduction

Parkinson's disease (PD) is a neurodegenerative disorder for which there is currently no disease modifying treatment but a number of symptomatic therapies. The disease is clinically defined by its motor features, which include rigidity, bradykinesia, resting tremor, and postural and gait disturbances. PD patients are also affected by a variety of nonmotor deficits such as hyposmia, autonomic dysfunction, sleep disturbances, cognitive impairment, and psychiatric symptoms [1]. The core pathology is the loss of dopaminergic neurons of the substantia nigra, although many other neuronal populations are also affected including the noradrenergic locus coeruleus, serotonergic raphe nucleus, and cholinergic basal forebrain systems as well as range of other structures such as the cortex, olfactory bulb, and even the enteric nervous system. Whilst the loss of the dopaminergic nigrostriatal pathway is the classical biochemical deficit in PD, pathologically it is the formation of Lewy bodies. Lewy bodies are composed of insoluble protein aggregates mainly made up of the protein α -synuclein (α -syn).

While this summary is a useful starting point in our understanding of PD, it is only an approximation of the true nature of this disorder as the disease is now recognised to be very heterogeneous at both the clinical and pathological levels [2]. Therefore, better classifying subtypes of PD will be necessary as will be the need to understand the differences in disease pathogenesis at the cellular and systems levels in these different forms of PD.

One approach, which holds great promise in terms of dissecting the different cellular events underlying the genesis of different subtypes of disease, is the area of cellular reprogramming of somatic cells from PD individuals themselves. Following the seminal demonstration that differentiated human somatic cells could be reprogrammed into a pluripotent state by the overexpression of a set of defined transcription factors (Oct4, Sox2 with either the combinations of Klf4 and Myc or Nanog, and Lin28) [3–5], the door to a whole new field of research has been opened. This technology using induced pluripotent stem (iPS) cells allows for cells to be grown from patients themselves which have

- (1) the capacity to proliferate indefinitely in culture;
- (2) a pluripotency profile, such that they can in theory be differentiated into any cell type, including neurons and more specifically dopaminergic nerve cells. iPS cells thus hold great promise for the *in vitro* modeling of neurodegenerative disorders, including PD.

More recently, it has been shown that one can actually directly reprogram human somatic cells into neurons, thereby avoiding the pluripotent state. This is also another emerging alternative approach to study patient-specific pathological disease processes. These reprogrammed cells could also be extremely useful for screening potential compounds for therapeutic purposes.

Since the first reports on human iPS cells and induced neurons (iN) were published, the field has moved forward at great speed, and in this paper, we present the highlights of the field as well as where it is going in terms of therapeutic applications.

2. Modeling PD with iPS Cells

iPS cells derived from patients offer a powerful *in vitro* model to study disease as these cells carry the necessary genetic risk factors for that disorder. The first iPS cells generated from PD patients were derived from fibroblasts harvested from skin biopsies and provided the first opportunity to truly study human pathological processes and drug development *in vitro* [6].

One of the first studies to successfully produce midbrain dopaminergic neurons from mouse iPS cells obtained neurons that expressed a number of markers specific to the midbrain dopaminergic system such as *Nurr1*, *Pitx3*, and tyrosine hydroxylase (TH) and had an electrophysiological pattern characteristic of nigral dopaminergic neurons [7]. Subsequently, human iPS cells were also efficiently differentiated into committed neural stem cells and dopaminergic neurons (iDA) using identical differentiation protocols to those used for human embryonic stem (ES) cells. Using such protocols, 30% TH differentiation was achieved, and the functionality of these neurons was further demonstrated by iDA survival with improvements in behavioral deficits when they were grafted into 6-hydroxydopamine- (6-OHDA-) lesioned rats [8]. Other groups have now further refined the differentiation protocol to obtain a more reliable and efficient production of iDA by either modulating FGF/ERK signaling [9] or by genetic engineering iPS cells with lentiviral vectors regulating the expression of *Lmx1a* [10].

At least 10 subtypes of dopaminergic neurons exist in the adult brain (A8–A17) [23], all of which show specific electrophysiological, neurochemical, and transcriptional profiles [24–26]. Ventral midbrain dopaminergic neurons—especially those found in the substantia nigra—are those most vulnerable to degeneration in PD [27, 28], and it is known that these A9 nigral dopaminergic neurons are needed in cell transplants to restore function in animal models of PD [12, 29–31]. If we hope to use iN to model PD, it is imperative that these neurons are genuine human midbrain nigral neurons. With this in mind, a human iPS cell

differentiation protocol targeting both early dorsalizing and ventralizing neural patterning pathways has been proposed [12]. Using this protocol, differentiated cells expressed all of the relevant markers, although electrophysiological studies were not performed which limits what one can say about these cells.

Several groups have now been able to produce PD patient-specific iDA derived from iPS cells. The first of these used fibroblasts from idiopathic PD patient and showed that iDA derived from iPS cells, regardless of the underlying disease or the age of the donor, did not show any disease-related phenotype [11]. This particular study also highlighted that residual transgene expression in virus-carrying iPS cells influenced their molecular properties and recommended that derivation methods free of reprogramming factors should be used.

This led to the first proof of concept study in which iDA derived from iPS cells from sporadic and LRRK2-associated PD patients displayed distinct disease-specific pathology [13]. In contrast, Soldner and colleagues [11] found no differences between the iDA from PD patients and controls in any measure after 30 days in culture. In their study, the majority of iN expressed the ventral midbrain dopaminergic neuronal phenotype, as compared to only 10% in the previous reports [11, 13]. However, time *in vitro* may have been a more critical factor here, as the long-term culture (<75 days) of iDA derived from sporadic PD cases revealed an altered morphology in PD-iDA, in particular, a decrease in the number and length of neurites and an increased susceptibility to degeneration and defective autophagosome clearance [13].

While the vast majority of PD cases are idiopathic (>85%), several causative genes have been identified in families displaying Mendelian inheritance of the disorder [32]. As a result, one obvious application of iDA is to study dopaminergic neuronal behavior associated with these genetic mutations. Thus far, four PD-related genes have been studied using iPS cell technology: *SNCA*, *Leucine-rich repeat kinase 2 (LRRK2)*, phosphatase and tensin homolog (*PTEN*)-induced putative kinase 1 (*PINK1*), and *Parkin* (Table 1).

2.1. SNCA. Alpha *SNCA* is the gene coding for α -syn, the main component of Lewy bodies [33]. It was also the first gene with mutations identified to cause autosomal dominant PD. Thus far, four different missense mutations (A53T, A30P, E46K, and H50Q) have been linked to familial PD, as well as duplications and triplications of the entire gene [34, 35]. So far, iPS cell lines from patients carrying a triplication of *SNCA* have been generated and differentiated into iDA [16]. While the fibroblasts did not express α -syn, a two fold increase in α -syn mRNA and protein expression was reported in patient-derived iDA when compared to cells from unaffected first-degree relatives sharing a similar genetic background. This provides the first proof-of-principle that this type of approach is viable to study Mendelian genetically driven pathological processes involved in α -synucleinopathies. However, given

TABLE 1: Summary of studies that have used dermal fibroblasts from PD patients to model the disease.

Forms of PD	Source of cells	Main findings	References
Sporadic	Dermal fibroblasts	PD-specific iPS cells are able to generate dopaminergic neurons	[11]
	↓		
	iPSC	New human iPS cell differentiation protocol to produce vmDA neuron	[12]
	↓ iDA	Morphological alterations (reduced numbers of neuritis and neurite arborization), accumulation of autophagic vacuoles	[13]
	Dermal fibroblasts	Rapid and efficient induction of iDA from human PD patient fibroblasts	[14]
	↓ iDA		
Familial			
SNCA triplication	Dermal fibroblasts	Accumulation of α -syn, inherent overexpression of markers of oxidative stress, and sensitivity to peroxide induced oxidative stress	[15]
	↓		
SNCA triplication	iPSC	Production of double the amount of α -syn as neurons from the unaffected relative	[16]
	↓		
SNCA A53T mutation	iN/iDA	Successful genetic repair of the mutation	[17]
LRRK2 G2019S mutation	Dermal fibroblasts	Increased expression of key oxidative stress-response genes and α -syn protein. Increased sensitivity to caspase-3 activation and cell death caused by exposure to stress agents	[18]
	↓		
LRRK2 G2019S mutation	iPSC	Morphological alterations (reduced numbers of neurites and neurite arborization), accumulation of autophagic vacuoles	[13]
	↓		
LRRK2 G2019S, R1441C mutations	iDA	Vulnerability associated with mitochondrial dysfunction which could be rescued with coenzyme Q10, rapamycin, and the LRRK2 inhibitor GW5074	[19]
Parkin mutation		Increased transcription of monoamine oxidases and oxidative stress, reduced DA uptake and increased spontaneous DA release	[20]
	Dermal fibroblasts		
	↓		
PINK1 mutation	iPSC	Impaired recruitment to lentivirally expressed parkin to mitochondria, increased mitochondria copy number, upregulation of PGC-1 α ; corrected by lentiviral expression of wild-type PINK1	[21]
	iDA		
PINK1 Q456X mutation		Vulnerability associated with mitochondrial dysfunction which could be rescued with coenzyme Q10, rapamycin, and the LRRK2 inhibitor GW5074	[19]
Risk gene			
	Dermal fibroblasts		
	↓		
Glucocerebrosidase	iPSC	Dramatic increase in α -syn protein levels with accumulation of α -syn, which results in neurotoxicity through aggregation dependent mechanisms	[22]
	↓		
	iDA		

Abbreviations: α -syn: α -synuclein; DA: dopamine; iDA: induced dopaminergic neurons; iPSC: induced pluripotent stem; LRRK2: Leucine-rich repeat kinase 2; PD: Parkinson's disease; PGC-1 α Peroxisome proliferator-activated receptor- γ coactivator 1 α ; SNCA: α -synuclein gene; vmDA: ventral mesencephalon dopaminergic.

the significant variability of clonal variation and efficiency of differentiation, this study also highlights the importance of generating multiple iPS cell lines from a single individual to identify clones with the capacity to differentiate into cell type of interest and also to compare neuronal cultures with equivalent differentiation efficiency [35].

A subsequent study to differentiate iPS cell lines into neurons from patients carrying a triplication of *SNCA* has further reported an accumulation of α -syn, overexpression of markers of oxidative stress, and increased sensitivity to peroxide-induced oxidative stress [15]. These findings suggest that these features are, at least in part, cell autonomous and that this approach with iPS cells can be a valuable way to study pathophysiological processes in the relevant cells from patients with specific genetic abnormalities. In this study, both TH-positive and TH-negative neurons exhibited ubiquitinated intracellular inclusions [15], indicating that patient-derived iPS cells with *SNCA* triplication can also be used to investigate selective vulnerabilities across neuronal subtypes associated with overexpression of wild-type α -syn.

One of the main considerations in modelling diseases by iPS cells *in vitro* includes the difficulty in distinguishing subtle disease-relevant phenotypic changes and how relevant these are to what takes place in the patients aging central nervous system (CNS). The lack of genetically matched controls combined with the high variability of the biological characteristics of the cells and cell lines derived from a single healthy donor are also important hurdles [11, 36, 37]. In an attempt to overcome these obstacles, Soldner and colleagues (2011) generated human iPS cell lines from patients carrying the A53T (G209) mutation in the *SNCA* gene which they then corrected using zinc finger nuclease-mediated genome editing [17]. They further confirmed the loss of expression of the A53T mutated transcript and demonstrated that this genetic repair did not compromise the ability to differentiate into iDA. By so doing, they generated iDA that differed only in this gene (i.e., a gene which gives the cell its susceptibility for PD), providing genetically matched control cells to study the effects of that specific mutation. However, while this approach is appealing to study cellular mechanisms associated with Mendelian forms of PD, it excludes the use of iPS cell lines to investigate idiopathic PD as such mutations do not exist.

Intracellular protein interactions relevant to PD have also been tackled using iDA reprogrammed from iPS cells derived from patients carrying a mutation in the *glucocerebrosidase* gene. This mutation is known to alter sphingolipid metabolism and has also been linked to parkinsonism [38]. Indeed, it has been suggested that there is a bidirectional effect of α -syn and *glucocerebrosidase* which acts to form a positive feedback loop that leads to a self-propagating disease. Namely, the *glucocerebrosidase* mutations jeopardize lysosomal protein degradation leading to aggregation of α -syn and neurotoxicity. Conversely, in iDA with wild-type *glucocerebrosidase*, α -syn inhibits lysosomal activity, suggesting that a loss of *glucocerebrosidase* in some patients with PD and a *glucocerebrosidase* heterozygote mutation could catalyse α -syn aggregation and by so doing contribute to the pathogenesis of their PD [22].

2.2. *LRRK2*. Mutations in the *LRRK2* gene have been reported to be the most frequent cause of late-onset autosomal dominant, as well as sporadic, PD [39, 40]. However, these mutations give rise to inconsistent pathological features, ranging from Lewy body inclusions to a strictly nigral degeneration with an absence of Lewy bodies [41]. *LRRK2* is a kinase with many domains which is capable of controlling many protein-protein interactions. While it is thought that changes in *LRRK2* protein domains can influence kinase activity by interfering with other proteins [42], the mechanism underlying the pathogenesis of *LRRK2*-PD patients is currently unknown. Studies of iPS cells derived from a single patient carrying the G2019S mutation in the *LRRK2* gene demonstrated increased accumulation of α -syn, an upregulation of key oxidative stress response genes and a selective vulnerability of TH-positive iN to neurotoxins, including H_2O_2 , MG-132, and 6-OHDA [18]. As for iDA derived from sporadic PD cases, Sánchez-Danés and colleagues (2012) have reported that long-term cultures of iDA carrying a *LRRK2* mutation displayed abnormal morphology, defective autophagosome clearance, and increased susceptibility to degeneration. Consistent with previous findings, aberrant diffuse cytoplasmic accumulation of α -syn in iDA differentiated from these *LRRK2*-PD iPS cells was also observed when compared to both control and idiopathic PD-derived iPS cells [13]. Furthermore, iN derived from patients carrying either the homozygous G2019S or the heterozygous R1441C show that while the mitochondrial electron transport chain is intact, these cells exhibit a neuronal cell type-specific increased sensitivity to mitochondria chemical stressors that depolarize mitochondria using K^+ ions but not protons (H^+) [19]. This suggests that *LRRK2* is involved in the cell ability to respond to mitochondria damaged by the influx of K^+ ions.

2.3. *Parkin* and *PINK1*. Mutations in the *parkin* gene are a cause of autosomal recessive PD, which usually manifests early in life. Indeed, homozygous mutations in *parkin* are the most frequent causes of juvenile PD. This early onset form of the disease is characterized by nigral neuronal loss and gliosis but rarely has Lewy bodies. The Parkin protein functions as an E3 ubiquitin ligase to conjugate ubiquitin proteins to lysine residues of target proteins [43].

PINK1 is a mitochondrial kinase for which pathogenic mutations are the second most common cause of autosomal recessive early onset PD [44]. Loss-of-function mutations in the gene are thought to either compromise the kinase activity of *PINK1* or interfere with its protein stability [45, 46].

Both Parkin and *PINK1* are involved in mitochondrial function [47], and *PINK1* has been suggested to function upstream of Parkin [48–50]. Midbrain iDA reprogrammed from iPS cells derived from skin fibroblasts of PD patients with *parkin* mutation exhibit increased spontaneous dopamine release and uptake, as well as an elevation in reactive oxygen species production. Of note, lentiviral expression of *parkin*, but not its PD-linked mutant, rescues these phenotypes. However, mitochondria are not seemingly

affected in these cells and the levels of TH and α -syn expression are not different when compared to cells from control subjects. [20]. In contrast, a further study showed that in human iDA carrying an endogenous *PINK1* mutation, Parkin did not translocate to mitochondria, suggesting that mutations in *PINK1* result in diminished recruitment of Parkin. This impairment was abrogated by the expression of normal *PINK1*. In addition, as opposed to wild-type iDA, mitochondrial DNA did not decrease in depolarized mutant *PINK1* iDA [21].

As it has been demonstrated for *LRRK2* mutations, iN cells carrying a recessive homozygous Q456X *PINK1* mutation show an impaired capacity to respond to mitochondria damaged by the influx of K^+ ions. These cells are also less able to respond to oxidative stress. Vulnerability to chemical stressors could be rescued by the antioxidant coenzyme Q_{10} and a *LRRK2* inhibitor, but not rapamycin [19]. This suggests that the increased production of ROS induced by the loss of *PINK1* could be associated with *LRRK2* functions.

While a relatively small amount of studies employing iPS cells from PD patients harboring a genetic mutation have been performed, they have been instrumental in clarifying some of the roles of critical proteins underlying familial forms of PD and their interactions with one another. These studies can further provide clues on how to tackle cell-autonomous pathological mechanisms in relevant neurons from idiopathic PD patients who represent the vast majority of cases. However, they are not able to investigate how different cellular compartments (e.g., glial cells) may interact in the overall disease process.

3. Modelling PD with Direct Neuronal Conversion

In recent years, neurons differentiated from iPS cells have provided new insights into the cellular mechanisms involved in the pathophysiology of PD. However, concerns remain with respect to their utility to do this given that they are reprogrammed back to a more pluripotent stage. To overcome this issue, several groups have developed methods that allow direct conversion of human differentiated somatic cells, such as fibroblasts, into functional neurons avoiding a pluripotent state.

The first proof-of-concept study was achieved by the conversion of mouse embryonic and postnatal fibroblasts into functional neurons by the overexpression of three transcription factors (*Ascl1*, *Brn2*, and *Myt1l*). These iN displayed neuronal properties such as the generation of action potentials as well as synapse formation [51]. Human fibroblasts have also been successfully converted into functional neurons by overexpressing the same transcription factors [52]. Several subsequent studies have been undertaken with the aim of optimizing these conversion methods. For example, functional neurons have been generated using two of the aftermentioned factors (*Brn2* and *Myt1l*) with the addition of a microRNA (*miR-124*) [53] or with the combination of microRNAs (*miR-124* and *miR-9/9**) and *NeuroD2* [54]. While these methods generated cells that

exhibited both electrophysiological and morphological characteristics typical of neurons, their neuronal subtype identity remained unclear.

The ability to convert human fibroblasts into functional glutamatergic forebrain neurons has been shown with cells from Alzheimer's disease patients, using a combination of four transcription factors (*Ascl1*, *Brn2*, *Myt1l*, and *Zic1*) [55]. The addition of two further transcription factors specific for the dopaminergic lineage (*Lmx1a* and *FoxA2*) is also sufficient to generate cells expressing TH and a dopaminergic morphology with a 10% conversion efficiency [52]. Furthermore, the reduction of this combination of transcription factors to only three (*Ascl1*, *Nurr1*, and *Lmx1a*) was sufficient to obtain cells with a dopaminergic neuronal-like morphology and appropriate electrophysiological properties [14]. However, the gene expression profiles of these reprogrammed DA neurons differed significantly from primary midbrain DA neurons in these studies, and so more recent attempts to generate iDA-like midbrain dopaminergic neurons have used six reprogramming factors (*Ascl1*, *Pitx3*, *Nurr1*, *Lmx1a*, *Foxa2*, and *En1*), as well as the patterning factors *Shh* and *FGF8* [56]. The iDA so generated expressed the generic dopaminergic markers TH, dopamine transporter (DAT), aromatic L-amino acid decarboxylase (AADC), and vesicular monoamine transporter 2 (VMAT2) and were also shown to release dopamine but only partially restored dopamine system functions *in vivo* in animal models of PD. These iDA cells also failed to show similar levels of the relevant transcription factors when compared to embryonic or adult midbrain dopamine neurons [56]. More recently, a combination of five transcription factors (*Ascl1*, *Pitx3*, *Nurr1*, *Sox2*, and *Ngn2*) generated iDA that were able to better reverse deficits when grafted into the 6-OHDA rat model of PD, suggesting that these reprogrammed cells display more properties of functional midbrain dopaminergic neurons [57].

Because the direct conversion does not go through a proliferative state, the quantity of neurons that can be obtained is limited by the accessible number of fibroblasts used as starting material for conversion. Nevertheless, direct conversion of patient's fibroblasts into relevant neuronal subtypes is very promising for disease modeling as well as potentially being useful for autologous cell therapy.

4. iDA as a Cell Therapy Source for Grafting in PD

Cell therapy is one of the promising experimental therapeutic approaches currently being tested in the clinic in patients with PD. However, ethical and logistical issues associated with the use of human fetal tissue prevent the widespread adoption of these cells in the clinical setting. The use of ES cells has been proposed as an alternative, mainly because these cells have the potential to generate all type of cells and provide an unlimited source of donor tissue [58]. However, the use of these cells has been hampered by (i) ethical issues, (ii) their tumourigenic potential; (iii) their ability to generate

sufficient numbers of true nigral dopaminergic neurons; (iv) the possible immune rejection of them due to host-donor immunological incompatibilities. Thus efforts have been made towards developing protocols that result in large numbers of nigral dopaminergic neurons, in the absence of any proliferative cell type or immune reaction to them.

iDA generated from iPS cells derived from the skin fibroblasts of patients are very appealing in this respect. Indeed, do these cells circumvent not only ethical issues associated with the use of fetal tissue, but also the risk of immune rejection. One other benefit in using iPS cells is the possibility of rejuvenating the cells from an aged patient and thus eliminating the pathologies associated with aging including the risk of Lewy body pathology in the transplant. This potential for iDA derived from iPS cells to be used as a cell replacement therapy has been assessed in the 6-OHDA rat model of PD. Studies have shown that grafted iPS cells functionally integrate into the host brain, and a large proportion of them differentiate into dopaminergic neurons expressing relevant markers such as TH, En1, VMAT2, and DAT four weeks following grafting [7]. While the vast majority of grafted animals showed behavioral improvements [7], continuous proliferation of transplanted cells, reminiscent of teratomas, was observed in some cases, and this raises serious safety concerns with their use [7, 59]. Differentiated iN and iDA have also been grafted in the 6-OHDA lesioned rat. Here, it has been shown that a small proportion of iN send out nondopaminergic connections into the surrounding white matter and that the iDA themselves had TH+ fibers that projected more within the graft than the host striatum [60]. These grafted cells did though provide a degree of functional recovery in amphetamine and apomorphine-induced rotational asymmetry in the majority of animals but failed to show improvement in behavioral tests that rely more on the connectivity of iDA with the host striatum, such as the cylinder test and the adjustment stepping test [60].

Moreover, several subpopulations of iDA were found within the graft, including a small number of forebrain- and hippocampal-like DA neurons. Transplantation of differentiated cells did not, though, generate teratomas.

Directly converted iDA from fibroblasts have also been transplanted into 6-OHDA lesioned rodents [56, 57]. Grafted mouse midbrain-like iDA, reprogrammed from tail tip fibroblasts, maintained their neuronal morphology, extended TH+ fibers into the host striatum, generated a rise in local dopamine levels and improved amphetamine-induced rotational behavior two months posttransplantation [56]. Human iDA also retained their dopaminergic neuron-like properties *in vivo* for up to 4 months post-transplantation [57].

Several proof-of-concept studies have thus been undertaken to show the capacity of iPS cells and iDA to provide functional recovery in toxin-induced animal models of PD. However, a number of questions remain to be answered such as the following.

Do these cells really form mature nigral dopaminergic neurons with their characteristic axonal outgrowth and arborisation?

How safe are these cells when used in this way?

Do these cells retain disease-specific vulnerability that will adversely affect their long-term beneficial effects?

In the case of Mendelian forms of PD, can we repair disease-related mutations *in vitro* and transplant corrected cells?

Can these cells be reprogrammed to replace all the cell losses seen in this disease?

5. Advantages and Limitations of the Use of Fibroblast-Derived Cells to Mimic PD Pathology

iPS cells have enormous potential for better understanding and treating PD but they also present a number of problems, some of which, but perhaps not all, will be resolved as the technology evolves. The clear advantage of using iDA derived from skin fibroblasts is that these cells are patient-specific, primary human cells which are easily available and relatively easy to culture. These cells thus provide multiple possibilities in the field of personalized medicine, with the potential for drug screening/testing on a range of affected neuronal cell populations.

There are also concerns with the use of iPS cell technology to study age-related pathologies such as PD. The induction of pluripotency is accompanied with a progressive elongation of telomeres with passaging [61–64], thus rejuvenating the cells in a similar way to the embryonic stem cell state, even in cells derived from aged individuals. However, the telomere chromatin returns to a mature state, similar to the one they were originally in when harvested, when differentiated again. iPS cells also retain DNA methylation patterns that are indicative of their original state before derivation [65–67]. The use of differentiated cells derived from iPS cells to model PD can be hampered by aberrant chromatin formation at the telomere level or elsewhere, making them more predisposed to telomere shortening and/or malignant transformation [68]. Going through the iPS cell stage creates reprogrammed iN that could be too young to exhibit PD phenotypes, and it has been suggested that it may therefore be necessary to accelerate PD-related phenotypes with exogenous stressors such as *in vitro* exposure to oxidative stress, neurotoxins, or overexpression of PD-associated proteins [11]. In this respect, longer culture times maybe all that is necessary, and indeed it has been shown that with iDA, the expression of these phenotypes does occur with increasing time in culture [13].

One other challenge that has to be overcome when modelling diseases using somatic cells as a primary source is the variable biological characteristics of cells from healthy donors as controls. Aspects that can vary include differences in genetic background, as well as in the cell derivation and differentiation processes [11, 36, 37], along with the genetic alterations introduced during the reprogramming process [69, 70]. Finally, whether human iPS cells are ever truly equivalent to the cell type into which they are being reprogrammed at the molecular and functional levels is another question that still needs to be answered [71].

Several major obstacles still remain to be overcome before the use of iPS therapy can be routinely performed in the clinic. Safety is a large concern, as these cells should be free from genetic aberrations and capable of differentiating into fully committed cells. A better understanding of the gene profiling that guides their development and differentiation would allow for the development of newer, safer techniques for human iPS cell derivation. Moreover, understanding the best approach to evaluate the properties of human iPS cell-derived differentiated cells and compare them with their natural counterparts *in vivo* will be critical in this regard. While exogenously used factors can be turned off during and after reprogramming, the possibility that they could either be turned back on during differentiation or that they could integrate and aberrantly activate oncogenes still exists. Although much work is therefore needed to optimize reprogramming methods and ensure a safe and efficient means of neuronal derivation, as well as their detailed cellular behavior, researchers have been increasingly hopeful that iPS cells or iDA will be a source of cells for studying disease pathogenesis as well as possibly cell replacement therapy in PD.

6. Somatic Cells for Future Alternative PD Modelling

PD is a complex disorder involving multiple systems and various cell types, including both neurons and glia. The ability to model PD using the conversion of somatic cells from PD patients would therefore benefit from the development of cocultures of multiple induced cell lineages. Aside from iDA, successful differentiation into neuronal subtypes includes glutamatergic neurons [72–74], GABAergic neurons [75], and motorneurons [76, 77]. Differentiation into an astrocyte lineage has been demonstrated with human iPS cells [78–83], although these cells represent only a small proportion of the total neural cells in culture. A recent study has induced neural stem cells from mouse fibroblasts using a shorter version of the reprogramming protocol, and these cells retained the capacity to differentiate into the three main neural lineages neurons, astrocytes, and oligodendrocytes [84]. Human iPS cells derived from fetal fibroblasts can also be differentiated into endothelial cells and recapitulate angiogenesis both *in vitro* and *in vivo* [85]. While microglia have been generated from mouse embryonic stem cells [86] and lineage-negative bone marrow cells from adult mice [87], successful reprogramming of somatic cells, such as fibroblasts into this cell type, has yet to be reported.

Studying the cellular pathology of different cell types could unravel their role in disease processes and by so doing help in the development of better therapeutic approaches. For example, in addition to iN reprogrammed from iPS cells derived from Huntington's disease patients that display changes in electrophysiology, metabolism, cell adhesion, and cell vulnerability to stressors [88], induced astrocytes exhibit cytoplasmic empty vacuoles [89], an abnormal phenotype that has been observed in peripheral blood lymphoblasts harvested from Huntington's disease patients [90]. While the

role of these vacuoles is not known, these findings underline the importance of assessing disease-specific phenotypes within each cell type involved in the pathophysiology of the disease. Furthermore, the establishment of an *in vitro* system in which multiple types of cells affected in PD could coexist would clearly provide additional information as to how they interact within the PD brain to generate the disease state.

7. Conclusions

Because iPS cells and directly converted cells from fibroblasts circumvent many of the ethical considerations that surround the use of ES cells, as well as originating from the patient themselves, they offer a wide range of possibilities for mainstream clinical use across the globe. One promising therapeutic application would be to generate iPS cells from patients that have genetic diseases, repair the genetic defect, differentiate the cells into the desired phenotype, and then reintroduce them into the patient. These cells could also be helpful *in vitro* in identifying new pathogenic pathways as well as novel biomarkers for individuals at risk of developing PD or complications of it (e.g., PD dementia). While a tremendous amount of work is still needed to reach these goals, the derivation of iPS cells from both familial and idiopathic PD patients to model the disease *in vitro* uniquely allows for therapeutic cell manipulations that cannot be performed *in vivo*. This will ultimately define in different subgroups of patients whether a given mutation or more complex gene interaction provides a cellular vulnerability or whether the disease process requires additional environmental or epigenetic factors. Although still in its infancy, the diversity of applications associated with the use of iPS and directly converted cells from fibroblasts makes this field of research one of the most promising for the *in vitro* modeling of PD and through this, the derivation of truly novel therapeutic approaches.

Acknowledgments

The work of R. A. Barker is supported by an NIHR award of Biomedical Research Centre to Addenbrooke's Hospital and the University of Cambridge.




References

- [1] K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, "Non-motor symptoms of Parkinson's disease: diagnosis and management," *The Lancet Neurology*, vol. 5, no. 3, pp. 235–245, 2006.
- [2] S. J. G. Lewis and R. A. Barker, "Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity," *Journal of Clinical Neuroscience*, vol. 16, no. 5, pp. 620–625, 2009.
- [3] W. E. Lowry, L. Richter, R. Yachechko et al., "Generation of human induced pluripotent stem cells from dermal fibroblasts," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 8, pp. 2883–2888, 2008.

- [4] K. Takahashi, K. Tanabe, M. Ohnuki et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors," *Cell*, vol. 131, no. 5, pp. 861–872, 2007.
- [5] J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., "Induced pluripotent stem cell lines derived from human somatic cells," *Science*, vol. 318, no. 5858, pp. 1917–1920, 2007.
- [6] I. H. Park, N. Arora, H. Huo et al., "Disease-specific induced pluripotent stem cells," *Cell*, vol. 134, no. 5, pp. 877–886, 2008.
- [7] M. Wernig, J. P. Zhao, J. Pruszak et al., "Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 15, pp. 5856–5861, 2008.
- [8] A. Swistowski, J. Peng, Q. Liu et al., "Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions," *Stem Cells*, vol. 28, no. 10, pp. 1893–1904, 2010.
- [9] I. Jaeger, C. Arber, J. R. Risner-Janiczek et al., "Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells," *Development*, vol. 138, no. 20, pp. 4363–4374, 2011.
- [10] A. Sánchez-Danés, A. Consiglio, Y. Richaud et al., "Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells," *Human Gene Therapy*, vol. 23, no. 1, pp. 56–69, 2012.
- [11] F. Soldner, D. Hockemeyer, C. Beard et al., "Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors," *Cell*, vol. 136, no. 5, pp. 964–977, 2009.
- [12] O. Cooper, G. Hargus, M. Deleidi et al., "Differentiation of human ES and Parkinson's disease iPSC cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid," *Molecular and Cellular Neuroscience*, vol. 45, no. 3, pp. 258–266, 2010.
- [13] A. Sánchez-Danés, Y. Richaud-Patin, I. Carballo-Carbajal et al., "Disease-specific phenotypes in dopamine neurons from human iPSC-based models of genetic and sporadic Parkinson's disease," *EMBO Molecular Medicine*, vol. 4, no. 5, pp. 380–395, 2012.
- [14] M. Caiazzo, M. T. Dell'Anno, E. Dvoretzkova et al., "Direct generation of functional dopaminergic neurons from mouse and human fibroblasts," *Nature*, vol. 476, no. 7359, pp. 224–227, 2011.
- [15] B. Byers, B. Cord, H. N. Nguyen et al., "SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress," *PLoS ONE*, vol. 6, Article ID e26159, 2011.
- [16] M. J. Devine, M. Ryten, P. Vodicka et al., "Parkinson's disease induced pluripotent stem cells with triplication of the α -synuclein locus," *Nature Communications*, vol. 2, no. 1, article 440, 2011.
- [17] F. Soldner, J. Laganière, A. W. Cheng et al., "Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations," *Cell*, vol. 146, no. 2, pp. 318–331, 2011.
- [18] H. N. Nguyen, B. Byers, B. Cord et al., "LRRK2 mutant iPSC-derived da neurons demonstrate increased susceptibility to oxidative stress," *Cell Stem Cell*, vol. 8, no. 3, pp. 267–280, 2011.
- [19] O. Cooper, H. Seo, S. Andrabi et al., "Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease," *Science Translational Medicine*, vol. 4, no. 141, Article ID 141ra90, 2012.
- [20] H. Jiang, Y. Ren, E. Y. Yuen et al., "Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells," *Nat Commun*, vol. 3, article 668, 2012.
- [21] P. Seibler, J. Graziotto, H. Jeong, F. Simunovic, C. Klein, and D. Krainc, "Mitochondrial parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells," *Journal of Neuroscience*, vol. 31, no. 16, pp. 5970–5976, 2011.
- [22] J. R. Mazzulli, Y. H. Xu, Y. Sun et al., "Gaucher disease glucocerebrosidase and α -synuclein form a bidirectional pathogenic loop in synucleinopathies," *Cell*, vol. 146, no. 1, pp. 37–52, 2011.
- [23] N. Prakash and W. Wurst, "Development of dopaminergic neurons in the mammalian brain," *Cellular and Molecular Life Sciences*, vol. 63, no. 2, pp. 187–206, 2006.
- [24] S. L. Ang, "Transcriptional control of midbrain dopaminergic neuron development," *Development*, vol. 133, no. 18, pp. 3499–3506, 2006.
- [25] D. A. McRitchie, C. D. Hardman, and G. M. Halliday, "Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans," *Journal of Comparative Neurology*, vol. 364, no. 1, pp. 121–150, 1996.
- [26] H. Neuhoff, A. Neu, B. Liss, and J. Roeper, "Ih channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain," *Journal of Neuroscience*, vol. 22, no. 4, pp. 1290–1302, 2002.
- [27] P. Damier, E. C. Hirsch, Y. Agid, and A. M. Graybiel, "The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease," *Brain*, vol. 122, no. 8, pp. 1437–1448, 1999.
- [28] E. Hirsch, A. M. Graybiel, and Y. A. Agid, "Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease," *Nature*, vol. 334, no. 6180, pp. 345–348, 1988.
- [29] S. Grealish, M. E. Jönsson, M. Li, D. Kirik, A. Björklund, and L. H. Thompson, "The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease," *Brain*, vol. 133, no. 2, pp. 482–495, 2010.
- [30] S. Kriks, J. W. Shim, J. Piao et al., "Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease," *Nature*, vol. 480, pp. 547–551, 2011.
- [31] N. S. Roy, C. Cleren, S. K. Singh, L. Yang, M. F. Beal, and S. A. Goldman, "Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes," *Nature Medicine*, vol. 12, no. 11, pp. 1259–1268, 2006.
- [32] S. Lesage and A. Brice, "Parkinson's disease: from monogenic forms to genetic susceptibility factors," *Human Molecular Genetics*, vol. 18, no. 1, pp. R48–R59, 2009.
- [33] M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, " α -synuclein in Lewy bodies," *Nature*, vol. 388, no. 6645, pp. 839–840, 1997.
- [34] J. Drouin-Ouellet, C. Gibrat, M. Bousquet, F. Calon, J. Kriz, and F. Cicchetti, "The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration," *Journal of Neuroinflammation*, vol. 8, article 137, 2011.
- [35] C. Klein and A. Westerberger, "Genetics of Parkinson's disease," *Cold Spring Harbor Perspectives in Medicine*, vol. 2, Article ID a008888, 2012.

- [36] C. Bock, E. Kiskinis, G. Verstaappen et al., "Reference maps of human es and ips cell variation enable high-throughput characterization of pluripotent cell lines," *Cell*, vol. 144, no. 3, pp. 439–452, 2011.
- [37] G. L. Boulting, E. Kiskinis, G. F. Croft et al., "A functionally characterized test set of human induced pluripotent stem cells," *Nature Biotechnology*, vol. 29, no. 3, pp. 279–287, 2011.
- [38] E. Sidransky, M. A. Nalls, J. O. Aasly et al., "Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease," *The New England Journal of Medicine*, vol. 361, no. 17, pp. 1651–1661, 2009.
- [39] S. Lesage, A. Dürr, M. Tazir et al., "LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs," *The New England Journal of Medicine*, vol. 354, no. 4, pp. 422–423, 2006.
- [40] L. J. Ozelius, G. Senthil, R. Saunders-Pullman et al., "LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews," *The New England Journal of Medicine*, vol. 354, no. 4, pp. 424–425, 2006.
- [41] B. I. Giasson, J. P. Covy, N. M. Bonini et al., "Biochemical and pathological characterization of Lrrk2," *Annals of Neurology*, vol. 59, no. 2, pp. 315–322, 2006.
- [42] D. MacLeod, J. Dowman, R. Hammond, T. Leete, K. Inoue, and A. Abeliovich, "The familial Parkinsonism gene LRRK2 regulates neurite process morphology," *Neuron*, vol. 52, no. 4, pp. 587–593, 2006.
- [43] R. J. Deshaies and C. A. P. Joazeiro, "RING domain E3 ubiquitin ligases," *Annual Review of Biochemistry*, vol. 78, pp. 399–434, 2009.
- [44] E. M. Valente, S. Salvi, T. Ialongo et al., "PINK1 mutations are associated with sporadic early-onset Parkinsonism," *Annals of Neurology*, vol. 56, no. 3, pp. 336–341, 2004.
- [45] E. Deas, H. Plun-Faureau, and N. W. Wood, "PINK1 function in health and disease," *EMBO Molecular Medicine*, vol. 1, no. 3, pp. 152–165, 2009.
- [46] S. Kawajiri, S. Saiki, S. Sato, and N. Hattori, "Genetic mutations and functions of PINK1," *Trends in Pharmacological Sciences*, vol. 32, no. 10, pp. 573–580, 2011.
- [47] A. Pils and K. F. Winklhofer, "Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease," *Acta Neuropathologica*, vol. 123, pp. 173–188, 2012.
- [48] D. P. Narendra, S. M. Jin, A. Tanaka et al., "PINK1 is selectively stabilized on impaired mitochondria to activate Parkin," *PLoS Biology*, vol. 8, no. 1, Article ID e1000298, 2010.
- [49] A. Rakovic, A. Grünewald, P. Seibler et al., "Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients," *Human Molecular Genetics*, vol. 19, no. 16, Article ID ddq215, pp. 3124–3137, 2010.
- [50] C. Vives-Bauza, C. Zhou, Y. Huang et al., "PINK1-dependent recruitment of Parkin to mitochondria in mitophagy," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 1, pp. 378–383, 2010.
- [51] T. Vierbuchen, A. Ostermeier, Z. P. Pang, Y. Kokubu, T. C. Südhof, and M. Wernig, "Direct conversion of fibroblasts to functional neurons by defined factors," *Nature*, vol. 463, no. 7284, pp. 1035–1041, 2010.
- [52] U. Pfisterer, A. Kirkeby, O. Torper et al., "Direct conversion of human fibroblasts to dopaminergic neurons," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 25, pp. 10343–10348, 2011.
- [53] R. Ambasudhan, M. Talantova, R. Coleman et al., "Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions," *Cell Stem Cell*, vol. 9, no. 2, pp. 113–118, 2011.
- [54] A. S. Yoo, A. X. Sun, L. Li et al., "MicroRNA-mediated conversion of human fibroblasts to neurons," *Nature*, vol. 476, pp. 228–231, 2011.
- [55] L. Qiang, R. Fujita, T. Yamashita et al., "Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons," *Cell*, vol. 146, no. 3, pp. 359–371, 2011.
- [56] J. Kim, S. C. Su, H. Wang et al., "Functional integration of dopaminergic neurons directly converted from mouse fibroblasts," *Cell Stem Cell*, vol. 9, no. 5, pp. 413–419, 2011.
- [57] X. Liu, F. Li, E. A. Stubblefield et al., "Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells," *Cell Research*, vol. 22, no. 2, pp. 321–332, 2012.
- [58] P. H. Lerou and G. Q. Daley, "Therapeutic potential of embryonic stem cells," *Blood Reviews*, vol. 19, no. 6, pp. 321–331, 2005.
- [59] J. Cai, M. Yang, E. Poremsky, S. Kidd, J. S. Schneider, and L. Iacovitti, "Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats," *Stem Cells and Development*, vol. 19, no. 7, pp. 1017–1023, 2010.
- [60] G. Hargus, O. Cooper, M. Deleidi et al., "Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 36, pp. 15921–15926, 2010.
- [61] R. M. Marion, K. Strati, H. Li et al., "Telomeres Acquire Embryonic Stem Cell Characteristics in Induced Pluripotent Stem Cells," *Cell Stem Cell*, vol. 4, no. 2, pp. 141–154, 2009.
- [62] R. Mathew, W. Jia, A. Sharma et al., "Robust activation of the human but not mouse telomerase gene during the induction of pluripotency," *FASEB Journal*, vol. 24, no. 8, pp. 2702–2715, 2010.
- [63] S. T. Suhr, E. A. Chang, R. M. Rodriguez et al., "Telomere dynamics in human cells reprogrammed to pluripotency," *PLoS ONE*, vol. 4, no. 12, Article ID e8124, 2009.
- [64] S. Yehezkel, A. Rebibo-Sabbah, Y. Segev et al., "Reprogramming of telomeric regions during the generation of human induced pluripotent stem cells and subsequent differentiation into fibroblast-like derivatives," *Epigenetics*, vol. 6, no. 1, pp. 63–75, 2011.
- [65] K. J. Hewitt, Y. Shamis, R. B. Hayman et al., "Epigenetic and phenotypic profile of fibroblasts derived from induced pluripotent stem cells," *PLoS ONE*, vol. 6, no. 2, Article ID e17128, 2011.
- [66] K. Kim, A. Doi, B. Wen et al., "Epigenetic memory in induced pluripotent stem cells," *Nature*, vol. 467, no. 7313, pp. 285–290, 2010.
- [67] Y. Ohi, H. Qin, C. Hong et al., "Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells," *Nature Cell Biology*, vol. 13, no. 5, pp. 541–549, 2011.
- [68] H. Ly, "Telomere dynamics in induced pluripotent stem cells: potentials for human disease modeling," *World Journal of Stem Cells*, vol. 3, pp. 89–95, 2011.
- [69] A. Gore, Z. Li, H.-L. Fung et al., "Somatic coding mutations in human induced pluripotent stem cells," *Nature*, vol. 471, no. 7336, pp. 63–67, 2011.
- [70] S. M. Hussein, N. N. Batada, S. Vuoristo et al., "Copy number variation and selection during reprogramming to pluripotency," *Nature*, vol. 471, no. 7336, pp. 58–62, 2011.
- [71] M. Stadtfeld and K. Hochedlinger, "Induced pluripotency: history, mechanisms, and applications," *Genes and Development*, vol. 24, no. 20, pp. 2239–2263, 2010.

- [72] N. Farra, W.-B. Zhang, P. Pasceri, J. H. Eubanks, and M. W. Salter, "Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations," *Molecular Psychiatry*, vol. 17, no. 12, pp. 1261–1271, 2012.
- [73] E. Pedrosa, V. Sandler, A. Shah et al., "Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells," *Journal of Neurogenetics*, vol. 25, no. 3, pp. 88–103, 2011.
- [74] H. Zeng, M. Guo, K. Martins-Taylor et al., "Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells," *PLoS ONE*, vol. 5, no. 7, Article ID e11853, 2010.
- [75] B. A. DeRosa, J. M. Van Baaren, G. K. Dubey et al., "Derivation of autism spectrum disorder-specific induced pluripotent stem cells from peripheral blood mononuclear cells," *Neuroscience Letters*, vol. 516, pp. 9–14, 2012.
- [76] J. T. Dimos, K. T. Rodolfa, K. K. Niakan et al., "Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons," *Science*, vol. 321, no. 5893, pp. 1218–1221, 2008.
- [77] B. Y. Hu and S. C. Zhang, "Differentiation of spinal motor neurons from pluripotent human stem cells," *Nature Protocols*, vol. 4, no. 9, pp. 1295–1304, 2009.
- [78] L. Emdad, S. L. D'Souza, H. P. Kothari, Z. A. Qadeer, and I. M. Germano, "Efficient differentiation of human embryonic and induced pluripotent stem cells into functional astrocytes," *Stem Cells and Development*, vol. 21, no. 3, pp. 404–410, 2012.
- [79] B. Y. Hu, J. P. Weick, J. Yu et al., "Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 9, pp. 4335–4340, 2010.
- [80] R. Krencik, J. P. Weick, Y. Liu, Z. J. Zhang, and S. C. Zhang, "Specification of transplantable astroglial subtypes from human pluripotent stem cells," *Nature Biotechnology*, vol. 29, no. 6, pp. 528–534, 2011.
- [81] R. Krencik and S. C. Zhang, "Directed differentiation of functional astroglial subtypes from human pluripotent stem cells," *Nature Protocols*, vol. 6, pp. 1710–1717, 2011.
- [82] S. Ruiz, K. Brennand, A. D. Panopoulos, A. Herreras, F. H. Gage, and J. C. Izpisua-Belmonte, "High-efficient generation of induced pluripotent stem cells from human astrocytes," *PLoS ONE*, vol. 5, no. 12, Article ID e15526, 2010.
- [83] S. H. Yuan, J. Martin, J. Elia et al., "Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells," *PLoS ONE*, vol. 6, no. 3, Article ID e17540, 2011.
- [84] M. Thier, P. Worsdorfer, Y. B. Lakes et al., "Direct conversion of fibroblasts into stably expandable neural stem cells," *Cell Stem Cell*, vol. 10, pp. 473–479, 2012.
- [85] Z. Li, S. Hu, Z. Ghosh, Z. Han, and J. C. Wu, "Functional characterization and expression profiling of human induced pluripotent stem cell- and embryonic stem cell-derived endothelial cells," *Stem Cells and Development*, vol. 20, pp. 1701–1710, 2011.
- [86] C. Beutner, K. Roy, B. Linnartz, I. Napoli, and H. Neumann, "Generation of microglial cells from mouse embryonic stem cells," *Nature Protocols*, vol. 5, no. 9, pp. 1481–1494, 2010.
- [87] D. Noto, K. Takahashi, S. Miyake, and M. Yamada, "In vitro differentiation of lineage-negative bone marrow cells into microglia-like cells," *European Journal of Neuroscience*, vol. 31, no. 7, pp. 1155–1163, 2010.
- [88] The HD iPSC Consortium, "Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes," *Cell Stem Cell*, vol. 11, no. 2, pp. 264–278, 2012.
- [89] T. A. Juopperi, W. R. Kim, C. H. Chiang et al., "Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells," *Mol Brain*, vol. 5, article 17, 2012.
- [90] E. Nagata, A. Sawa, C. A. Ross, and S. H. Snyder, "Autophagosome-like vacuole formation in Huntington's disease lymphoblasts," *NeuroReport*, vol. 15, no. 8, pp. 1325–1328, 2004.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

